Antibody-directed Therapies for COVID-19 • Etesevimab plus Bamlanivimab - Effective against spike protein of SARS-CoV-2 - Prevents viral attachment and inhibits entry into human cells - For treatment of mild to moderate COVID-19 infection which is suspected to progress in adult and adolescents - Note: Viral variants show resistance to Bamlanivimab therefore it is no more used as monotherapy. • Casirivimab plus Imdevimab - Binds to two points in the viral structure of SARS-CoV-2 - For treatment of mild to moderate COVID 19 infection which is suspected to progress in children aged 12 or older and weigh 40 kg or more - Note: Not effective with Bamlanivimab.